Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02951221 · ClinicalTrials.gov registry record · Phase 1
New Formulation and Food Effect Study of BIIB074
A Phase 1 study of Trigeminal Neuralgia (TN) and Other Neuropathic Pain, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT02951221: Completed Phase 1 study of Trigeminal Neuralgia (TN) and Other Neuropathic Pain, sponsored by Biogen.
NCT02951221 is a Phase 1 study of Trigeminal Neuralgia (TN) and Other Neuropathic Pain that has completed, run by Biogen. The registered enrollment target is 28 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02951221, a Phase 1 study of Trigeminal Neuralgia (TN) and Other Neuropathic Pain, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objectives of the study are to assess the relative bioavailability of the BIIB074 direct compression formulation (DCF) to the BIIB074 roller compaction formulation (RCF) and to determine the effect of a high-fat meal on the pharmacokinetics (PK) of the BIIB074 DCF. The secondary objective of the study is to assess the safety and tolerability of BIIB074 administered as the DCF following single oral dose administration in healthy participants.
Conditions Studied
Interventions
- DRUG BIIB074 Treatment A
- DRUG BIIB074 Treatment B
- DRUG BIIB074 Treatment C
- DRUG BIIB074 Treatment D
Study Locations (1)
Florida
- Research Site - Daytona Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-12 |
| Est. Completion | 2017-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02951221
The ClinicalTrials.gov registry entry for NCT02951221 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Trigeminal Neuralgia (TN) appearing as the primary indexed condition, and to 4 interventions - of which BIIB074 Treatment A is the first listed.
NCT02951221 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT02951221 about?
NCT02951221 is a clinical study titled "New Formulation and Food Effect Study of BIIB074". The primary objectives of the study are to assess the relative bioavailability of the BIIB074 direct compression formulation (DCF) to the BIIB074 roller compaction formulation (RCF) and to determine the effect of a high-fat meal on the pharmacokinetics (PK) of the BIIB074 DCF. The secondary objectiv...
What is the current status of trial NCT02951221?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2016-12. Estimated completion is 2017-02.
What conditions does trial NCT02951221 study?
This clinical trial studies the following conditions: Trigeminal Neuralgia (TN), Other Neuropathic Pain.
What interventions are being tested in trial NCT02951221?
The interventions under investigation include: BIIB074 Treatment A (DRUG), BIIB074 Treatment B (DRUG), BIIB074 Treatment C (DRUG), BIIB074 Treatment D (DRUG).
Who is sponsoring clinical trial NCT02951221?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02951221 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.